N. Nishimoto

Rheumatology · 2000–2008

A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Rheumatology — 10 citations into it; #99 of 221 by trust here, #25 by citations

Whom N. Nishimoto trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. T. Kishimoto

Who trusts N. Nishimoto overall

1. J. Smolen
2. B. K. Pedersen
3. T. Kishimoto
4. Hiroshi Takayanagi
5. I. McInnes
6. Simon A. Jones
7. Markus F. Neurath

Papers from N. Nishimoto's perspective

Ordered by how strongly the researchers N. Nishimoto trusts endorse each paper. Same corpus, a different order for every researcher.

1. Humanized anti-interleukin-6 receptor antibody
2. A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate (Cancer Science)
3. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. (Arthritis & Rheumatism)
4. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
5. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. (Journal of Clinical Investigation)
6. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. (Gastroenterology)
7. Interleukin 6: from bench to bedside (Nature Clinical Practice Rheumatology)
8. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. (New England Journal of Medicine)
9. Longitudinal data analysis using generalized linear models
10. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. (Journal of Rheumatology)

Their papers

• TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling (2004) — 676 citations
• Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. (2008) — 738 citations
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. (2008) — 767 citations
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab (2007) — 729 citations
• Interleukin 6: from bench to bedside (2006) — 625 citations
• Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. (2004) — 786 citations
• A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. (2004) — 647 citations
• Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo (2000) — 1,336 citations